Recipient: Dr Alex Swarbrick
Institute: Garvin Institute of Medical Research
Funding: $385,000 July 2012 to June 2016
Dr Alex Swarbrick’s project from the Garvan Institute of Medical Research focuses on microRNAs, a class of small molecules that regulate gene expression and that have also been shown to drive neuroblastoma aggressiveness.
Researchers in Dr Swarbrick’s group have identified a number of microRNAs that dramatically sensitise neuroblastoma cells to chemotherapy in vitro, highlighting the therapeutic potential of his work, in particular with regards to chemoresistant neuroblastoma.
The ultimate aim of this study is to develop a novel treatment that will target microRNAs specific to neuroblastoma, leading to better response and reduced side effects.